Oxidative Stress Markers In Inherited Homocystinuria And The Impact Of Taurine
Cystathionine beta-synthase deficiency is an inherited disease that results in elevation of a substance called homocysteine (Hcy) in blood and urine. Individuals with this disorder have a very high risk for developing blood clots and are at risk for developing eye and bone abnormalities. Current treatments are generally difficult to follow and can fail. Development of additional therapies has been limited by lack of understanding of how the disease works.
The purpose of this study is to see if oxidative stress and inflammation are involved in the disease process and if short-term supplementation with taurine is an effective treatment.
Funding source: FDA-OOPD
|Study Design:||Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Oxidative Stress Markers In Inherited Homocystinuria And The Impact Of Taurine|
- Biomarkers associated with oxidative stress and inflammation;tumor necrosis factor (TNF)-alpha and thiobarbituric acid reactive substances (TBARS) [ Time Frame: 4 1/2 days ] [ Designated as safety issue: No ]
- Pharmacokinetics of Taurine [ Time Frame: 4 1/2 days ] [ Designated as safety issue: No ]
- Biochemical and Clinical Safety Data [ Time Frame: During study and 2 weeks after completion ] [ Designated as safety issue: Yes ]
- Blood vessels and platelet function study [ Time Frame: 4 1/2 days ] [ Designated as safety issue: No ]
- Taurine Pharmacokinetics [ Time Frame: 4 1/2 days ] [ Designated as safety issue: No ]
- Multiple Biomarkers of Inflammation and Oxidative Stress [ Time Frame: 4 1/2 days ] [ Designated as safety issue: No ]
- Relation to Biochemical Parameters of Homocystinuria [ Time Frame: 4 1/2 days ] [ Designated as safety issue: No ]
- Bone Mineral Density [ Time Frame: Lifetime ] [ Designated as safety issue: No ]
|Study Start Date:||January 2010|
|Estimated Study Completion Date:||December 2015|
|Estimated Primary Completion Date:||June 2015 (Final data collection date for primary outcome measure)|
Treatment with Taurine
Take Taurine for 4 1/2 days, two doses per day
Other Name: Not Applicable. No other names.
Cystathionine beta-synthase deficient homocystinuria(CBSDH) is an inherited disease that results in elevation of a substance called homocysteine(Hcy)in blood and urine. Individuals with this disorder have a very high risk for developing blood clots that can cause a stroke or other life-threatening problems. In addition, these individuals have bone and joint tissue abnormalities.
Current treatment with an extremely strict diet and medication (betaine) is very difficult to follow, and often fails. Development of additional treatment strategies has been limited by a lack of knowledge and understanding of how this disease works. Hence, there is a need to better understand what causes the blood clots and the bone and joint tissue abnormalities.
New data suggest that oxidative stress and inflammation play a central role in animals with this disease. Limited data on humans with this disease support this as well. Further, data from animals with this disease suggests that taurine, a natural body substance and food product, which is low in these patients, mitigates this effect. This study is designed to follow-up on these data.
The purpose of the study is to increase our understanding of the disease process in this disorder, and to see in a pilot study if short-term supplementation with taurine is an effective intervention. The aims of the study are to:
- see if substances (markers) associated with oxidative stress and inflammation are increased in individuals with CBSDH
- see if the levels of these markers relate to the levels of homocysteine
- see if the levels of these markers decrease with short-term taurine supplementation
- see how bood vessels and platelets (small substances in the blood that help blood clot) work in individuals with CBSDH, if their ability to work is related to levels of markers of oxidative stress and inflammation, and if taurine supplementation improves how they work
- see if alterations of bone strength are related to levels of markers of inflammation.
The hypotheses to be investigated are as follows:
- Biomarkers of oxidative stress and inflammation are increased in individuals with CBSDH
- The degree of elevation of the biomarkers of oxidative stress and inflammation is relative to the degree of elevation of homocysteine, the main accumulating substance for this disease.
- Treatment with taurine mitigates the elevation of biomarkers of oxidative stress and inflammation.
- Endothelial function (blood vessel function) is abnormal in individuals with CBSDH even when receiving standard therapy and is improved with taurine supplementation.
- Chronic platelet aggregation, a variable finding in individuals with CBSDH, is mitigated with taurine supplementation.
- Decreased bone mineral density relates to the increase in inflammatory markers in CBSDH.
In addition, baseline pharmacokinetics (how much taurine is in the blood) of oral pharmacologic doses of taurine will be developed.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01192828
|Contact: Cynthia Freehauf, RN CGCfirstname.lastname@example.org|
|Contact: Johan Van Hove, MD PhD MBAemail@example.com|
|United States, Colorado|
|Childrens Hospital Colorado||Recruiting|
|Aurora, Colorado, United States, 80045|
|Contact: Cindy Freehauf, MS, RN, CGC 303-724-2342 Cynthia.Freehauf@childrenscolorado.org|
|Contact: Johan Van Hove, MD 303-724-2336 Johan.Vanhove@childrenscolorado.org|
|Sub-Investigator: Cynthia Freehauf, MS, RN, CGC|
|Principal Investigator: Johan Van Hove, MD, PhD|
|University of Colorado||Recruiting|
|Aurora, Colorado, United States, 80045|
|Contact: Cindy Freehauf, MS, RN, CGC 303-724-2342 firstname.lastname@example.org|
|Contact: Johan Van Hove, MD, PhD 303-724-2336 email@example.com|
|Principal Investigator: Johan Van Hove, MD PhD MBA|
|Sub-Investigator: Kenneth MacLean, PhD|
|United States, Pennsylvania|
|Childrens Hospital of Philadelphia||Recruiting|
|Philadelphia, Pennsylvania, United States, 19104|
|Contact: Can Ficicioglu, MD 215-590-3376 FICICIOGLU@email.chop.edu|
|Contact: Jamie KOH, RN 215-590-0120 KOH@email.chop.edu|
|Principal Investigator:||Johan VanHove, MD PhD MBA||University of Colorado, Denver|